AR and neoplasm: A key mechanism of developing castration resistance and driving tumor progression is represented by molecular alterations of AR and in particular the generation of alternatively spliced variants of the full-length AR (AR-Vs), resulting in constitutive androgenic signaling because they lack the ligand-binding domain and the targeted drug site [81].